The FDA delayed its decision on AstraZeneca’s oral SERD camizestrant after a negative advisory committee vote tied to issues including study design and the quality of evidence. The review extension gives additional time to evaluate analyses requested by the regulator, after SERENA-6 results were submitted for a proposed treatment setting. The delayed timeline follows concerns raised by external FDA advisors around trial conduct, lack of certain survival evidence, and unclear effects on patient quality-of-life. AstraZeneca said the agency needs more time to review additional data requested to support the application. In parallel, European regulators have recommended approval for the regimen, increasing pressure for the US decision process while underscoring that evidence standards and endpoint expectations differ across regions. For biotech stakeholders, the practical impact is schedule uncertainty for market access planning and downstream payer negotiations for oral SERDs competing in endocrine-relapsed breast cancer strategies.